Investment Ideas

UnitedHealth Group (NYSE: UNH) — the Minnesota-based healthcare giant and leading provider of health insurance and services — has rebounded sharply after Warren Buffett's Berkshire Hathaway disclosed a $1.6 billion stake on August 15, 2025, sending shares up over 12%.

This move comes amid a challenging year for the stock, which had dropped nearly 40% year-to-date before the surge, making it one of the best undervalued stocks to buy now for investors seeking cheap stocks with strong fundamentals. The rally highlights UnitedHealth's resilient position in the evolving healthcare landscape, bolstered by its Optum division's AI-driven analytics and expansive insurance network.

As organizations increasingly adopt tech-enabled healthcare solutions, UNH is positioned as a frontrunner in a sector projected to grow trillions in value, offering compelling trade ideas for those scanning for stocks to buy right now.

Stock Snapshot (as of Aug 18, 2025)

Current Price: ~$306 (post-surge recovery)

Market Cap: ~$282 billion

YTD Performance: -37.75% (prior to recent surge; now recovering) 52-Week Range: $234.60 – $630.73

Why UnitedHealth Is Gaining Bullish Momentum

Strong Earnings Recovery & Raised Outlook – UnitedHealth delivered solid Q2 2025 results, with revenues climbing 13% year-over-year to $111.6 billion, driven by growth in UnitedHealthcare insurance and Optum services.

Despite an EPS miss in Q1 due to margin pressures, the company re-established its full-year guidance, projecting EPS around $16 for 2025 with growth to $16.80–$17 in 2026. Profitability remains robust, with a TTM EPS of $23.10 and operating margins holding steady, underscoring the business model's durability.

This performance has renewed investor confidence, positioning UNH as one of the best dividend stocks to buy now with a 2.91% yield and a recent 5.2% dividend hike.

Massive Healthcare Market Potential & UNH's Edge – The global healthcare market is exploding, with PwC estimating AI and digital health could contribute $15.7 trillion to the economy by 2030.

UnitedHealth's dual-platform approach — insurance via UnitedHealthcare and tech/services through Optum — gives it a competitive moat in data analytics, telehealth, and value-based care. Optum's AI tools are irreplaceable for payers and providers, offering high stickiness and scalability. Unlike rivals, UNH's integrated model captures synergies across the ecosystem, making it resilient to regulatory shifts and a top pick among undervalued stocks to buy now in a sector trading at just 16x earnings.

Surging Adoption and Partnerships – Customer growth accelerated in Q2, with UnitedHealthcare adding millions of members and Optum securing multi-year deals in pharmacy benefits and analytics. Total revenues hit a record $422.82 billion TTM, up significantly from prior years, fueled by expanding Medicare Advantage and commercial segments.

Key partnerships, like those with tech firms for AI integration, are extending UNH's reach into preventive care and population health. With over 40 high-value clients and a growing backlog, UNH's momentum signals sustained expansion, appealing to trade ideas scanners focused on reliable growth plays.

Growing Investor Enthusiasm – Buffett's $1.6 billion bet has ignited retail and institutional interest, with shares jumping 12.48% on the news.

Social media on X is buzzing, dubbing UNH the "next healthcare titan" amid its undervalued status. Analysts like Mizuho maintain a Buy rating, with an average target of $329.57 implying further upside. Even Bank of America notes a V-shaped recovery potential, despite near-term challenges.

CEO Andrew Witty's focus on efficiency and innovation resonates, with fervent bulls predicting a return to $500+ levels. This shift in sentiment, far outpacing conservative estimates, makes UNH a standout among stocks to buy right now for momentum traders.

Trade Setup & Targets

Buy Range: $290 – $310 – Post-Buffett surge,

UNH is consolidating around $306. Dips to the $290s offer attractive entries, with strong support at $280 from recent lows. This zone aligns with oversold conditions, ideal for value-oriented trade ideas.

Take-Profit Zone: $340 – $360 – Momentum could push UNH toward the mid-$300s soon, representing 10–15% upside. This targets psychological resistance and analyst averages, suitable for locking in gains amid volatility.

Upside Potential: ~+15% (to ~$350) – A climb to $350 would build on the recovery, supported by Buffett's vote of confidence and sector tailwinds. Bullish scenarios from X discussions eye $400+, but a modest 15% gain keeps it realistic for the best dividend stocks to buy now.

Suggested Stop-Loss: $270.00 – Place stops below $270, near the 52-week low, to manage risk. A break here could signal renewed downside, offering ~12% buffer from current levels while accounting for healthcare sector swings.

If UNH holds above $290 and forms higher lows, it could target $330 swiftly. Watch for a break above $310 to confirm bullish continuation; overhead resistance is light until $350. Conversely, failure to sustain gains might lead to consolidation in the $250–$280 range, presenting secondary buys for long-term holders.

With strong institutional backing, dips could attract buyers, but a drop below $250 warrants caution.

Risks to Watch

Stretched Valuation Amid Volatility – Despite a low PE of 13.48, UNH's 40% YTD drop reflects margin pressures and a DOJ probe into anticompetitive practices. Trading at elevated multiples relative to peers if growth slows, any market rotation from healthcare could amplify swings. At a $282B cap, volatility is inherent — prepare for 10–20% moves on news.

Competition and Adoption Hurdles – Rivals like Cigna and Elevance are ramping up AI investments, potentially eroding UNH's edge in Optum. Slower-than-expected adoption of value-based care or cost pressures from inflation could cap growth. If the healthcare "revolution" lags, UNH's trajectory might moderate.

Regulatory & Dependence Risks – Heavy reliance on government programs like Medicare Advantage exposes UNH to policy changes, rate cuts, or scrutiny. A new administration could alter reimbursements, while privacy laws might constrain data analytics. The ongoing DOJ investigation adds uncertainty.

Execution & Margin Challenges – To sustain growth, UNH must navigate cyberattack aftermaths and execute flawlessly on guidance. Any EPS slip or dilution from acquisitions could erode confidence. The ambitious $16 EPS target for 2025 demands precision in a high-cost environment.

Is UnitedHealth a Good Investment Idea?

Yes, UnitedHealth stands out as a compelling, undervalued investment for those betting on healthcare's long-term boom, especially with Buffett's endorsement signaling deep value. Its Q2 revenue surge, dividend reliability, and AI-driven platforms position it for recovery, with potential to dominate as digital health scales.

Partnerships and member growth validate the model, akin to a foundational player in a transformative industry. When icons like Buffett call it a buy amid dips, it's a strong case for one of the best undervalued stocks to buy now. However, UNH demands patience — volatility from regulations and margins makes it unsuitable for the risk-averse. Size positions wisely, monitoring quarterly updates and policy news. For conviction holders, dips are opportunities; traders might ride momentum. Ultimately, UNH's success hinges on executing in a dynamic sector, but its cheap valuation and growth prospects make it a solid pick among stocks to buy right now.

Do you think UnitedHealth will reclaim its highs and become the AI healthcare leader, or is the sector too risky? Share your thoughts in the comments below!

Disclaimer

This post is for informational purposes and reflects personal opinions based on public information and recent developments. It is not investment advice. Always do your own due diligence before making investment decisions.